CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


Dr. Patel on Mitigating CAR T-Cell Therapy­–Related CRS in Multiple Myeloma

September 16th 2021

Krina K. Patel, MD, MSc, discusses mitigating CAR T-cell therapy–related cytokine release syndrome in multiple myeloma.

Dr. Anderson on the Challenges Faced With CAR T-Cell Therapy in Myeloma

September 16th 2021

Larry Anderson, MD, PhD, discusses the challenges faced with CAR T-cell therapy in patients with multiple myeloma.

Dr. Shah on Unmet Needs With CAR T-Cell Therapy in Multiple Myeloma

September 15th 2021

Nina Shah, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Racial, Social Disparities Linked With T-Cell Lymphoma Outcomes

September 11th 2021

Existing racial and socioeconomic disparities among patients with T-cell non-Hodgkin lymphoma continue to lead to obstacles with access for newly available treatment options.

CAR T-Cell Therapies Show Promise Across Indolent Lymphomas

September 10th 2021

CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.

Cilta-Cel Emerges as Potential CAR T-Cell Option in Relapsed/Refractory Multiple Myeloma

September 10th 2021

The CAR T-cell therapy ciltacabtagene autoleucel has emerged as a potentially durable treatment strategy for patients with relapsed/refractory multiple myeloma who have progressed on 1 to 3 prior lines of treatment and are refractory to lenalidomide.

Dr. Patel on the Integration of CAR T-Cell Therapy in Multiple Myeloma

September 8th 2021

Krina K. Patel, MD, MSc, discusses the integration of CAR T-cell therapy into the treatment paradigm of relapsed/refractory multiple myeloma.

Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma

September 3rd 2021

Frits van Rhee, MD, PhD, discusses future research directions with CAR T-cell therapy for the treatment of patients with multiple myeloma.

Dr. Herrera on the Utility of CAR T-Cell Therapy in Hematologic Cancers

September 3rd 2021

Alex Herrera, MD, discusses the utility of CAR T cells in patients with hematologic cancers.

P-PSMA-101 Elicits Encouraging Responses in Metastatic Castration-Resistant Prostate Cancer

September 1st 2021

The autologous CAR T-cell therapy P-PSMA-101 elicited robust antitumor responses in patients with metastatic castration-resistant prostate cancer, according to preliminary findings from the phase 1 P-PSMA-101-001 trial that were virtually presented during the 6th Annual CAR-TCR Summit.

Second-Line Tisagenlecleucel Misses EFS End Point in Aggressive B-cell Non-Hodgkin Lymphoma

August 24th 2021

The CAR T-cell therapy tisagenlecleucel did not significantly improve event-free survival compared with standard of care when used in the second-line treatment of patients with aggressive B-cell non-Hodgkin lymphoma who had primary refractory disease or who relapsed within 12 months of frontline treatment.

Idecabtagene Vicleucel Approved in Europe for Relapsed/Refractory Multiple Myeloma

August 19th 2021

The European Commission has granted a conditional marketing authorization for idecabtagene vicleucel for use in adult patients with relapsed/refractory multiple myeloma who have previously received at least 3 therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody and progressed on their last therapy.

CAR T-Cell Therapy Use Requires Schooling of Adverse Event Recognition and Management

August 13th 2021

Due to the potency of CAR T-cell therapies and the associated adverse events that can to arise in patients receiving this type of treatment, oncology nurses need to be educated on how to best identify and manage these AEs.

Non–CAR T-Based Strategies Shake Up the Management of Non-Hodgkin Lymphoma

August 13th 2021

Stephen M. Ansell, MD, PhD, discusses recent progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.

Standardized Guidelines Support Management Strategies of CAR T-Cell Therapy–Related Toxicities

August 12th 2021

As more CAR T-cell therapies are approved for the treatment of patients with hematologic malignancies, adopting management strategies for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome using newly standardized grading criteria is an important component of utilizing these products in practice.

Ongoing Research Aims to Solidify CAR T-Cell Therapy’s Place in Non-Hodgkin Lymphoma

August 11th 2021

CAR T-cell therapy has proven to be an effective treatment option in non-Hodgkin lymphoma subtypes, such as diffuse large B-cell lymphoma, and mantle cell lymphoma.

Dr. Park on Selecting Among Available CAR T-Cell Therapies in MCL

August 5th 2021

Jae Park, MD, discusses the factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.

Novel Oncolytic Virus/Allogeneic CAR T-Cell Combo Under Development for Solid Tumors

August 4th 2021

The combination of a CF33-CD19 oncolytic virus technology and CyCART-19, is under development for use as a potential therapeutic option for patients with solid tumors.

Dr. Park on Emerging CAR T-Cell Therapies in Hematologic Malignancies

August 3rd 2021

Jae H. Park, MD, discusses emerging CAR T-cell therapies in hematologic malignancies.

Emerging Allogeneic CAR T Candidates Usher in a New Era

July 22nd 2021

Dose-dependent engraftment of the investigative CAR T-cell therapy CYAD-211 was demonstrated in the first patient with relapsed/refractory multiple myeloma to receive this dose in the phase 1 IMMUNICY-1 trial, and no graft-versus-host disease has been reported to date.